• Stryker (NYSE:SYK) has completed its acquisition of Amplitude Vascular Systems, adding new peripheral vascular technology focused on arterial disease.
• A law firm has launched a securities investigation into Stryker related to the March cyberattack and its reported impact on financial results.
• These developments come as Stryker continues recent M&A activity, following its Inari Medical deal, while also facing fresh legal and regulatory scrutiny.

Stryker enters these headlines with shares at $294.23, after a 6.6% decline over the past week and an 11.4% decline over the past month. The stock is also down 15.5% year to date and 22.3% over the past year. The 3 year and 5 year returns stand at 6.2% and 25.0%, respectively. That mix of shorter term pressure and longer term gains provides context for both the Amplitude Vascular Systems acquisition and the new investigation.

For shareholders, the completed deal extends Stryker’s reach in peripheral vascular care, while the securities probe adds a layer of headline and regulatory risk tied to the cyberattack. The evolution of these developments, including any findings from the investigation and the integration of Amplitude Vascular Systems, will be important for assessing the balance of opportunity and risk in NYSE:SYK.

Stay updated on the most important news stories for Stryker by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Stryker.

The Amplitude Vascular Systems deal gives Stryker another piece in peripheral arterial disease, an area where peers such as Medtronic and Boston Scientific also compete for hospital budgets. Amplitude’s intravascular lithotripsy technology is designed to fracture calcium in severely narrowed vessels, which can sit naturally alongside Stryker’s existing MedSurg and neurovascular tools and the clot-removal capabilities gained with Inari Medical. For you as an investor, the key question is whether Stryker can turn this broader portfolio into higher procedure volumes and better product mix without letting acquisition spending and integration costs drag on returns. At the same time, the new securities investigation tied to the March cyberattack adds an extra governance and legal overhang just as the company is working through weaker recent share-price performance and a Q1 earnings miss.

How This Fits Into The Stryker Narrative

• The acquisition supports the narrative around expansion in high-need procedure areas and deeper hospital relationships, which can help revenue growth and margin improvement if cross selling works as planned.
• The securities investigation highlights the risk that higher compliance costs, cyber related disruption and any regulatory outcomes could challenge the assumption of smooth execution and steady international expansion.
• The specific legal and reputational fallout from this cyberattack related probe is unlikely to be fully captured in longer term narratives that focus on demographics, robotics and emerging markets.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Stryker to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ The securities investigation related to the March cyberattack introduces headline, legal and potential financial risk that could weigh on sentiment if it escalates.
• ⚠️ Continued acquisition activity, including Amplitude Vascular Systems and Inari Medical, raises integration and capital allocation risk if expected synergies are slower or harder to realize.
• 🎁 Adding Amplitude’s intravascular lithotripsy technology extends Stryker’s peripheral vascular portfolio, which can help support procedure based growth alongside its existing orthopaedics and MedSurg businesses.
• 🎁 Recent data points such as Q1 2026 earnings, a higher year on year dividend and analyst flagged rewards around earnings growth and valuation signal that the business still has identified strengths despite current pressures.

What To Watch Going Forward

From here, it is worth tracking how quickly Amplitude’s technology is integrated into Stryker’s commercial channels and whether management discloses any revenue or margin contribution over time. On the risk side, keep an eye on updates about the cyberattack related securities investigation, including any official findings or settlements, and how customers respond to Stryker’s handling of cybersecurity. Given the recent 52 week low, the mix of acquisitions, legal scrutiny and dividend decisions will shape how the Stryker story develops for investors who already hold the stock or follow it closely.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Stryker, head to the community page for Stryker to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.